Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 1
2009 2
2010 1
2011 3
2012 1
2013 1
2014 4
2015 3
2016 6
2017 3
2018 1
2019 6
2020 7
2021 18
2022 22
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Asante KP, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, Neuzil KM, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 Study Team. Dayan GH, et al. Among authors: kibuuka h. Lancet Respir Med. 2023 Nov;11(11):975-990. doi: 10.1016/S2213-2600(23)00263-1. Epub 2023 Sep 13. Lancet Respir Med. 2023. PMID: 37716365 Clinical Trial.
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials.
Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG; COVID-19 Prevention Network. Mena Lora AJ, et al. JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974. JAMA Netw Open. 2023. PMID: 36689221 Free PMC article.
The Joint Mobile Emerging Disease Clinical Capability (JMEDICC) laboratory approach: Capabilities for high-consequence pathogen clinical research.
Naluyima P, Kayondo W, Ritchie C, Wandege J, Kagabane S, Tumubeere L, Kusiima B, Kibombo D, Atukunda S, Nanteza C, Nabirye H, Mugabi FB, Namuyanja S, Hatcher C, Rauch H, Mukembo M, Musinguzi P; JMEDICC Consortium; Sanders N, Turesson E, Cando C, Walwema R, Mimbe D, Hepburn J, Clark D, Lamorde M, Kibuuka H, Zaman S, Cardile AP, Martins KA. Naluyima P, et al. Among authors: kibuuka h. PLoS Negl Trop Dis. 2019 Dec 19;13(12):e0007787. doi: 10.1371/journal.pntd.0007787. eCollection 2019 Dec. PLoS Negl Trop Dis. 2019. PMID: 31856153 Free PMC article. Review.
Global variability of the human IgG glycome.
Štambuk J, Nakić N, Vučković F, Pučić-Baković M, Razdorov G, Trbojević-Akmačić I, Novokmet M, Keser T, Vilaj M, Štambuk T, Gudelj I, Šimurina M, Song M, Wang H, Salihović MP, Campbell H, Rudan I, Kolčić I, Eller LA, McKeigue P, Robb ML, Halfvarson J, Kurtoglu M, Annese V, Škarić-Jurić T, Molokhia M, Polašek O, Hayward C, Kibuuka H, Thaqi K, Primorac D, Gieger C, Nitayaphan S, Spector T, Wang Y, Tillin T, Chaturvedi N, Wilson JF, Schanfield M, Filipenko M, Wang W, Lauc G. Štambuk J, et al. Among authors: kibuuka h. Aging (Albany NY). 2020 Aug 12;12(15):15222-15259. doi: 10.18632/aging.103884. Epub 2020 Aug 12. Aging (Albany NY). 2020. PMID: 32788422 Free PMC article.
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
McLean C, Barry H, Kieh M, Anywaine Z, Tapima Rogers B, Doumbia S, Sirima SB, Serry-Bangura A, Habib Beavogui A, Gaddah A, Katwere M, Hendriks J, Keshinro B, Eholie S, Kibuuka H, Kennedy SB, Anzala O, Samai M, D'Ortenzio E, Leigh B, Sow S, Thiébaut R, Greenwood B, Watson-Jones D, Douoguih M, Luhn K, Robinson C. McLean C, et al. Among authors: kibuuka h. EBioMedicine. 2023 May;91:104562. doi: 10.1016/j.ebiom.2023.104562. Epub 2023 Apr 24. EBioMedicine. 2023. PMID: 37099841 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Mwesigwa B, Houser KV, Hofstetter AR, Ortega-Villa AM, Naluyima P, Kiweewa F, Nakabuye I, Yamshchikov GV, Andrews C, O'Callahan M, Strom L, Schech S, Anne Eller L, Sondergaard EL, Scott PT, Amare MF, Modjarrad K, Wamala A, Tindikahwa A, Musingye E, Nanyondo J, Gaudinski MR, Gordon IJ, Holman LA, Saunders JG, Costner PJM, Mendoza FH, Happe M, Morgan P, Plummer SH, Hickman SP, Vazquez S, Murray T, Cordon J, Dulan CNM, Hunegnaw R, Basappa M, Padilla M, Gajjala SR, Swanson PA 2nd, Lin BC, Coates EE, Gall JG, McDermott AB, Koup RA, Mascola JR, Ploquin A, Sullivan NJ, Kibuuka H, Ake JA, Ledgerwood JE; RV 508 Study Team. Mwesigwa B, et al. Among authors: kibuuka h. Lancet Infect Dis. 2023 Dec;23(12):1408-1417. doi: 10.1016/S1473-3099(23)00344-4. Epub 2023 Aug 3. Lancet Infect Dis. 2023. PMID: 37544326 Clinical Trial.
Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand.
Li Y, Merbah M, Wollen-Roberts S, Beckman B, Mdluli T, Swafford I, Mayer SV, King J, Corbitt C, Currier JR, Liu H, Esber A, Pinyakorn S, Parikh A, Francisco LV, Phanuphak N, Maswai J, Owuoth J, Kibuuka H, Iroezindu M, Bahemana E, Vasan S, Ake JA, Modjarrad K, Gromowski G, Paquin-Proulx D, Rolland M. Li Y, et al. Among authors: kibuuka h. Emerg Infect Dis. 2022 Nov;28(11):2214-2225. doi: 10.3201/eid2811.221041. Epub 2022 Oct 11. Emerg Infect Dis. 2022. PMID: 36220131 Free PMC article.
Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study.
Allahna E, Nicole D, Neha S, Hannah K, Jonah M, John O, Valentine S, Emmanuel B, Michael I, Trevor A C, Christina S P, Joseph S C, Julie A A; AFRICOS Study Group. Allahna E, et al. Among authors: hannah k. J Acquir Immune Defic Syndr. 2022 Nov 1;91(3):285-289. doi: 10.1097/QAI.0000000000003065. Epub 2022 Aug 18. J Acquir Immune Defic Syndr. 2022. PMID: 35980350 Free PMC article.
Routine HIV clinic visit adherence in the African Cohort Study.
Dear N, Esber A, Iroezindu M, Bahemana E, Kibuuka H, Maswai J, Owuoth J, Polyak CS, Ake JA, Crowell TA; AFRICOS Study Group. Dear N, et al. Among authors: kibuuka h. AIDS Res Ther. 2022 Jan 7;19(1):1. doi: 10.1186/s12981-021-00425-0. AIDS Res Ther. 2022. PMID: 34996470 Free PMC article.
Weight gain during the dolutegravir transition in the African Cohort Study.
Esber AL, Chang D, Iroezindu M, Bahemana E, Kibuuka H, Owuoth J, Singoei V, Maswai J, Dear NF, Crowell TA, Polyak CS, Ake JA; AFRICOS Study Group. Esber AL, et al. Among authors: kibuuka h. J Int AIDS Soc. 2022 Apr;25(4):e25899. doi: 10.1002/jia2.25899. J Int AIDS Soc. 2022. PMID: 35419973 Free PMC article.
97 results